Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Novocure Limited's Business Segments
Novocure Limited's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
France
Total Revenue
$ 184
Regions Reported
1
Revenue Share by Reportable Segment - FY
- France24.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| France | $ 44 | 24.1% |
Revenue Share by Region - FY
- Other international markets9.9%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Other international markets | $ 18 | 9.9% |
Annual Results
Revenue Share by Reportable Segment - FY
- France24.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| France | $ 44 | 24.1% |
Revenue Share by Region - FY
- Other international markets8.7%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Other international markets | $ 57 | 8.7% |
Description of Novocure Limited
Novocure Limited is a medical technology company that develops and commercializes innovative cancer treatments based on the combination of electric fields and chemotherapy to disrupt cancer cell division. The company was founded in 2000, and its headquarters are located in Jersey, United Kingdom. It operates with a team of over 1000 employees worldwide, including the United States, Switzerland, Japan, Israel, and Germany, among other countries.
Novocure aims to improve the lives of cancer patients by providing innovative, non-invasive cancer therapies that improve survival rates while maintaining the patient's quality of life. Its primary product, the Optune system, is an FDA-approved device that delivers Tumor Treating Fields (TTFields) to cancer cells, interrupting their division without the toxic side effects of chemotherapy. TTFields use low-intensity electric fields to inhibit cancer cell division, resulting in a slower tumor growth rate and better survival outcomes.
The company's products are used to treat brain tumors, mesothelioma, pancreatic cancer, and non-small cell lung cancer. Novocure has conducted extensive clinical trials on its products, engaging in over 12 clinical trials with a total of over 2000 patients, reporting positive results. The company has also published over 50 peer-reviewed articles showing the efficacy of its Optune system.
Apart from its product pipeline, Novocure has established collaborations with several renowned academic institutions worldwide, including Columbia University, Dartmouth College, and the Mayo Clinic. The company's clinical and R&D teams work closely with these institutions to advance research and clinical studies on cancer treatments.
Novocure Limited aims to become a world leader in cancer care by providing innovative cancer therapies that enhance patient outcomes and reduce treatment-related side effects. The company continues to invest in research & development and clinical studies to further expand the use of Tumor Treating Fields and improve cancer care globally.
Novocure aims to improve the lives of cancer patients by providing innovative, non-invasive cancer therapies that improve survival rates while maintaining the patient's quality of life. Its primary product, the Optune system, is an FDA-approved device that delivers Tumor Treating Fields (TTFields) to cancer cells, interrupting their division without the toxic side effects of chemotherapy. TTFields use low-intensity electric fields to inhibit cancer cell division, resulting in a slower tumor growth rate and better survival outcomes.
The company's products are used to treat brain tumors, mesothelioma, pancreatic cancer, and non-small cell lung cancer. Novocure has conducted extensive clinical trials on its products, engaging in over 12 clinical trials with a total of over 2000 patients, reporting positive results. The company has also published over 50 peer-reviewed articles showing the efficacy of its Optune system.
Apart from its product pipeline, Novocure has established collaborations with several renowned academic institutions worldwide, including Columbia University, Dartmouth College, and the Mayo Clinic. The company's clinical and R&D teams work closely with these institutions to advance research and clinical studies on cancer treatments.
Novocure Limited aims to become a world leader in cancer care by providing innovative cancer therapies that enhance patient outcomes and reduce treatment-related side effects. The company continues to invest in research & development and clinical studies to further expand the use of Tumor Treating Fields and improve cancer care globally.
Segments of Novocure Limited
Novocure Limited operates primarily in the field of oncology, focusing on cancer therapies through two main segments:
1. Commercial Segment: This segment is dedicated to the commercialization of Novocure’s FDA-approved Optune system, a non-invasive treatment designed primarily for glioblastoma (GBM) and malignant pleural mesothelioma (MPM). The Optune system harnesses innovative technology using electric fields to disrupt the proliferation of cancer cells, thus targeting tumors in the brain and lungs without the harmful side effects associated with traditional therapies.
2. Research and Development (R&D) Segment: The R&D segment focuses on the exploration and development of new cancer treatment methodologies using Novocures proprietary Tumor Treating Fields (TTFields) technology. This segment is tasked with leading clinical research efforts aimed at assessing the efficacy of TTFields for various cancer types beyond GBM and MPM. Ongoing clinical trials are aimed at expanding the application of TTFields technology to additional malignancies, including but not limited to pancreatic cancer, ovarian cancer, and brain metastases.
Products and Services Offered by Novocure Limited
1. Optune System:
- The flagship product of Novocure, the Optune system is an FDA-approved, non-invasive treatment device that utilizes TTFields to disrupt the growth of cancer cells, particularly in patients diagnosed with GBM and MPM.
- The system is designed to be portable, allowing patients to maintain their daily activities while receiving treatment. It consists of a portable electric field generator and transducer arrays that can be placed on the scalp or chest wall, delivering low-intensity, alternating electric fields directly to the tumor site.
2. Pipeline Products:
- Novocure maintains an active pipeline of investigational TTFields applications under clinical examination:
- TTFields plus Chemotherapy for Pancreatic Cancer: Promising a dual approach where electric fields complement traditional chemotherapy, potentially enhancing treatment efficacy.
- TTFields plus Chemotherapy for Ovarian Cancer: Aimed at evaluating the combinations effectiveness in managing this challenging cancer type.
- TTFields for Recurrent Glioblastoma: Population-specific studies focusing on patients whose tumors have returned after prior treatment.
- TTFields for Brain Metastases: This includes studies targeting patients whose cancer has spread to the brain, looking to improve outcomes through non-invasive methods.
3. Patient Support Services:
- Recognizing the complexities involved with cancer treatment, Novocure provides comprehensive patient support services to ensure that patients and their families have access to the resources they need. Services include:
- Patient Education and Training: Informational programs that help patients understand their treatment options, the benefits of TTFields, and how to use the Optune system effectively.
- Insurance and Reimbursement Assistance: Support in navigating insurance challenges, with dedicated teams that help patients secure necessary funding for their treatments.
- Community Outreach Programs: Initiatives designed to raise awareness of available treatment options and provide support networks for patients and caregivers.
4. Clinical Trials:
- Novocure is deeply engaged in clinical research, actively conducting numerous clinical trials to evaluate the safety and efficacy of its TTFields-based therapies across a variety of cancer types. Collaborations with leading medical institutions and researchers worldwide enhance the understanding of TTFields, bolstering the development of novel cancer therapies.
Summary
Overall, Novocure Limited is at the forefront of oncological innovation, offering pioneering products and services that target cancer treatment through non-invasive methods. The company aims to transform the standard of care for cancer patients using its unique TTFields technology, while also building a supportive ecosystem around patients to help ease their treatment journey. Through its commitment to ongoing research, Novocure seeks to expand its therapeutic offerings, potentially revolutionizing how various cancers are treated.
Novocure Limited operates primarily in the field of oncology, focusing on cancer therapies through two main segments:
1. Commercial Segment: This segment is dedicated to the commercialization of Novocure’s FDA-approved Optune system, a non-invasive treatment designed primarily for glioblastoma (GBM) and malignant pleural mesothelioma (MPM). The Optune system harnesses innovative technology using electric fields to disrupt the proliferation of cancer cells, thus targeting tumors in the brain and lungs without the harmful side effects associated with traditional therapies.
2. Research and Development (R&D) Segment: The R&D segment focuses on the exploration and development of new cancer treatment methodologies using Novocures proprietary Tumor Treating Fields (TTFields) technology. This segment is tasked with leading clinical research efforts aimed at assessing the efficacy of TTFields for various cancer types beyond GBM and MPM. Ongoing clinical trials are aimed at expanding the application of TTFields technology to additional malignancies, including but not limited to pancreatic cancer, ovarian cancer, and brain metastases.
Products and Services Offered by Novocure Limited
1. Optune System:
- The flagship product of Novocure, the Optune system is an FDA-approved, non-invasive treatment device that utilizes TTFields to disrupt the growth of cancer cells, particularly in patients diagnosed with GBM and MPM.
- The system is designed to be portable, allowing patients to maintain their daily activities while receiving treatment. It consists of a portable electric field generator and transducer arrays that can be placed on the scalp or chest wall, delivering low-intensity, alternating electric fields directly to the tumor site.
2. Pipeline Products:
- Novocure maintains an active pipeline of investigational TTFields applications under clinical examination:
- TTFields plus Chemotherapy for Pancreatic Cancer: Promising a dual approach where electric fields complement traditional chemotherapy, potentially enhancing treatment efficacy.
- TTFields plus Chemotherapy for Ovarian Cancer: Aimed at evaluating the combinations effectiveness in managing this challenging cancer type.
- TTFields for Recurrent Glioblastoma: Population-specific studies focusing on patients whose tumors have returned after prior treatment.
- TTFields for Brain Metastases: This includes studies targeting patients whose cancer has spread to the brain, looking to improve outcomes through non-invasive methods.
3. Patient Support Services:
- Recognizing the complexities involved with cancer treatment, Novocure provides comprehensive patient support services to ensure that patients and their families have access to the resources they need. Services include:
- Patient Education and Training: Informational programs that help patients understand their treatment options, the benefits of TTFields, and how to use the Optune system effectively.
- Insurance and Reimbursement Assistance: Support in navigating insurance challenges, with dedicated teams that help patients secure necessary funding for their treatments.
- Community Outreach Programs: Initiatives designed to raise awareness of available treatment options and provide support networks for patients and caregivers.
4. Clinical Trials:
- Novocure is deeply engaged in clinical research, actively conducting numerous clinical trials to evaluate the safety and efficacy of its TTFields-based therapies across a variety of cancer types. Collaborations with leading medical institutions and researchers worldwide enhance the understanding of TTFields, bolstering the development of novel cancer therapies.
Summary
Overall, Novocure Limited is at the forefront of oncological innovation, offering pioneering products and services that target cancer treatment through non-invasive methods. The company aims to transform the standard of care for cancer patients using its unique TTFields technology, while also building a supportive ecosystem around patients to help ease their treatment journey. Through its commitment to ongoing research, Novocure seeks to expand its therapeutic offerings, potentially revolutionizing how various cancers are treated.